Spots Global Cancer Trial Database for Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate

Official Title: BRAF, KRAS and EGFR Mutation Detection in Non-Small Cell Lung Cancer Patients Treated With Sorafenib Monotherapy

Study ID: NCT01124669

Conditions

Lung Cancer

Interventions

DNA analysis

mutation analysis

laboratory biomarker analysis

Study Description

Brief Summary: RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in blood samples from patients with refractory non-small cell lung cancer previously treated with sorafenib tosylate.

Detailed Description: OBJECTIVES: * To determine the mutation rates of BRAF, KRAS, and EGFR in patients with non-small cell lung cancer treated with sorafenib tosylate on protocol ECOG-2501. * To determine the association between BRAF, KRAS, or EGFR mutation status and clinical benefits in patients treated with this regimen. OUTLINE: This is a multicenter study. DNA is isolated from archived plasma samples and analyzed for BRAF, KRAS, and EGFR mutations.